Catheter Robot Atlas

Commercial and clinical-stage systems · ydhbns01_yidu2020

VAS HERO

YDHB-NS01 / VAS HERO
Yidu Hebei Robot Technology · 2020–2026
VAS HERO: main picture1 / 3
Not cleared for distribution. liu2024_efficacy Fig. 2(B), PMC image https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6f/11221321/099807b86682/svn-2022-002260f02.jpg (https://pmc.ncbi.nlm.nih.gov/articles/PMC11221321/). Licence: CC BY-NC 4.0. Picture grade C.
Family
Commercial and clinical-stage systems (commercial)
Devices
0.035-in guidewire + 5F catheter
Degrees of freedom
catheter advance+rotate, wire advance
Push
Linear stage
Twist
Not reported
Tested up to
Human
Sim-to-real
None found — No simulation-trained controller found for this robot.

Testing

Highest level
Human
What was tested
RCT 260 enrolled/257 done, 3 centres (liu2024_efficacy); 25+25 (liu2026_clinical)
Key numbers
success 100% both; operation time 47.94+-27.49 vs 48.59+-25.60 min (liu2024_efficacy); 27 vs 38 min p=0.005 (liu2026_clinical)

Mechanism

Push (translation)
linear-stage+clamp
Twist (rotation)
catheter carriage on linear axis; wire clamp-and-relay
Device range
N.R.
Target anatomy
neurovascular (cerebral angiography)

Sensing and interface

Force sensing
N.R.
Leader and haptics
no (steering handles, doctor console)
Imaging
bedside slave + remote console
Sterility
N.R.

Size

Footprint (mm)
N.R.
Mass (kg)
N.R.

Simulation

Simulation model
none found
Sim-trained controller
none found

Versions

Lineage
YDHB-NS01; v2.0 mentioned

Sources

  1. Efficacy and safety of a neurointerventional operation robotic assistance system in cerebral angiography · Stroke and Vascular Neurology, 2024 · doi:10.1136/svn-2022-002260 [liu2024_efficacy]
  2. Clinical validation and literature review of robot-assisted cerebral angiography · Chinese Neurosurgical Journal, 2026 · doi:10.1186/s41016-026-00426-w [liu2026_clinical]

Notes

Notes
NMPA Class III approval 2023-03-13 per cn-healthcare.com 2023-04-28 (named 易度河北, product VAS HERO). CONFLICT: other press attributes the first NMPA approval (2023-03-14, 260-pt, 100% success) to Beijing Wansi (万思) Medical; the 260-pt 3-centre trial matches liu2024_efficacy (YDHB-NS01), so Wansi attribution looks like a mix-up; unresolved without the NMPA database.

This record

Read level
full — full text on disk
Picture
liu2024_efficacy Fig. 2(B), PMC image https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6f/11221321/099807b86682/svn-2022-002260f02.jpg (https://pmc.ncbi.nlm.nih.gov/articles/PMC11221321/) ↗ — licence: CC BY-NC 4.0; grade C
Picture changes
cropped (422,0)-(783,228) of 783x574
Found by
commercial: Search of commercial and clinical-stage systems.
Data
JSON · YAML: records/robots/ydhbns01_yidu2020.yaml
Correction
Suggest a correction [repository not created yet]